JESSICA ABREU: Open Payments
NPI 1326898206 · EMERSON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$612 in 37 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $356 · 2025 $612
Food & beverage: $612
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $286 |
| Otsuka America Pharmaceutical, Inc. | 8 | $149 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| Almatica Pharma LLC | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $18 |
| E.R. Squibb & Sons, L.L.C. | 1 | $16 |
Products named: VRAYLAR, ABILIFY MAINTENA, REXULTI, UZEDY, LOREEV XR, TRINTELLIX, Qelbree, CAPLYTA.
Industry payments across NJ — which companies pay providers there.
